New Delhi, Nov 07: National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on MRP of 137 anti-cancer drugs, based on the recommendations of Expert Committee constituted by the Directorate General of Health Services (DGHS) under Ministry of Health & Family Welfare on 17th October, 2026. The revised prices of these drugs will come into effect from 9th November, 2026.
As on date, 76 pharmaceutical companies have reported revised MRP for 1225 anti-cancer formulations, covering 121 drugs. Reduction in the MRP have been reported in 1031 formulations of anti-cancer medicines, with 600 brands reporting above 50% reduction and the highest reduction being 96.45%.
Further, out of the 137 identified anti-cancer drugs, there are 10-15 drugs which are yet to be launched in India. However, Trade Margin Rationalization (TMR) will be applicable on these drugs also as and when they are launched. As a result of the price reductions to be effected from 9th November, 2026, the estimated annual savings to consumers would be ₹3,502.31 crore.
